MDxHealth S.A. (MDXH) is a Healthcare stock trading at $0.55 (as of 2026-06-18), with a market capitalization of $181.41M and a trailing P/E of -0.9. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
MDxHealth SA develops prostate cancer genomic testing products used in urologic care, including SelectMDx (a urine-based test) and ConfirmMDx (an epigenetic test). The company markets these solutions to clinicians across the United States and multiple European countries, including the Netherlands, Belgium, Spain, Poland, Italy, and other parts of the EU, as well as internationally.